Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher Peter Wayman is active.

Publication


Featured researches published by Christopher Peter Wayman.


British Journal of Pharmacology | 2008

Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1A receptors and not oxytocin receptors

J Gupta; R J Russell; Christopher Peter Wayman; D Hurley; V M Jackson

Oxytocin is believed to be involved in ejaculation by increasing sperm number and contracting ejaculatory tissues. However, oxytocin may mediate these effects via oxytocin or vasopressin (AVP) receptors. The aim of this study was to determine the effect of oxytocin and AVP on peripheral tissues involved in ejaculation and to identify the receptor subtype(s) involved.


British Journal of Pharmacology | 2009

Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro

K L Aughton; K Hamilton‐Smith; J Gupta; J S Morton; Christopher Peter Wayman; V M Jackson

Hypothalamic neuropeptides centrally modulate sexual arousal. However, the role of neuropeptides in peripheral arousal has been ignored. Vascular and non‐vascular smooth muscle relaxation in the vagina is important for female sexual arousal. To date, in vitro studies have focused on vaginal strips with no studies on vaginal arteries. The aim of this study was to compare the effects of sexual hypothalamic neuropeptides on rabbit vaginal wall strips and arteries.


The Journal of Sexual Medicine | 2010

An ex vivo multi-electrode approach to evaluate endogenous hormones and receptor subtype pharmacology on evoked and spontaneous neuronal activity within the ventromedial hypothalamus; translation from female receptivity.

Clair Booth; Christopher Peter Wayman; Vivienne Margaret Jackson

INTRODUCTION The ventromedial hypothalamus (VMH) controls female rodent copulatory behavior, which can be modulated by injection of various compounds into the VMH. Aim. The aim was to determine whether evoked excitatory postsynaptic potentials (EPSPs) or single-unit activity within the VMH ex vivo is a better parameter to predict lordosis. METHODS VMH slices were placed onto a 64 microelectrode chip and spontaneous single-unit activity was recorded or slices stimulated to evoke EPSPs. MAIN OUTCOME MEASURES The sodium channel blocker, tetrodotoxin and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate antagonist, 6,7-dinitroquinoxaline-2,3-dione (DNQX) inhibited EPSPs, confirming EPSPs were glutamatergic in origin. The GABA(A) antagonist bicuculline potentiated EPSPs implying endogenous GABA tone. Single-unit activity was abolished by tetrodotoxin but unaffected by DNQX or bicuculline. RESULTS Glutamatergic neurotransmission was greatest during metestrous and following ovariectomization. The number of regions within the VMH eliciting single-unit activity was reduced following ovariectomy without changing spike frequency. Adrenergic agents increasing lordosis via the VMH in vivo, decreased glutamate neurotransmission but increased single-unit activity. Conversely, agents decreasing lordosis via the VMH increased glutamatergic neurotransmission and inhibited single-unit activity (8-OH-DPAT, [D-Ala(2), N-Me-Phe(4), Gly-ol(5)]-enkephalin, corticotropin releasing factor, bicuculline). Melanocortin and pituitary adenylate cyclase-activating polypeptide agonists had no effect. CONCLUSIONS Here we present a novel, robust VMH in vitro technique that (i) is consistent with the hypothesis that glutamate via non-NMDA receptors inhibits lordosis; (ii) glutamate is under the endogenous tone of GABA and steroid hormones; (iii) inhibition of lordosis during metestrous and following ovariectomy potentiates glutamatergic neurotransmission; (iv) activation of G(q)- and G(i)-coupled receptors decreases and increases glutamate neurotransmission, respectively, with an inverse correlation on single-unit activity; (v) activation of G(s)-coupled receptors has no direct effect on glutamate or single-unit activity; and (vi) potency, receptor subtypes and localization can be determined prior to in vivo studies.


British Journal of Pharmacology | 2010

UK-414,495, a selective inhibitor of neutral endopeptidase, potentiates pelvic nerve-stimulated increases in female genital blood flow in the anaesthetized rabbit

Christopher Peter Wayman; D Baxter; L Turner; P H van der Graaf; Alasdair Mark Naylor

Background and purpose:  Female sexual arousal consists of a number of physiological responses resulting from increased genital blood. Vasoactive intestinal peptide (VIP), neuropeptide Y and to a lesser extent nitric oxide are neurotransmitters found in the vasculature of the genitalia. Neutral endopeptidase (NEP) modulates the activity of neuropeptides including VIP. The aim of this study was to investigate the control of genital blood flow by VIP and endogenous neuropeptides using a selective NEP inhibitor [UK‐414,495, ((R)‐2‐({1‐[(5‐ethyl‐1,3,4‐thiadiazol‐2‐yl) carbamoyl]cyclopentyl}methyl) valeric acid)].


Chemical Biology & Drug Design | 2006

The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.

Graham Nigel Maw; Alan Stobie; Simon Paul Planken; David C. Pryde; Vivienne Sanderson; Michelle Y. Platts; Martin Corless; Peter Stacey; Christopher Peter Wayman; Piet H. van der Graaf; Christopher Kohl; Sara Coggon; Kevin Beaumont

A series of small molecule glutaramides were synthesized and evaluated for potency against canine and human neutral endopeptidase using target criteria of molecular weight <400 and log P between 2 and 4.5 to maximize the likelihood of achieving good oral absorption. The structure‐activity relationship (SAR) investigations described in this paper led to the identification of an ethyl 1,3,4‐thiadiazole glutaramide which demonstrated good neutral endopeptidase potency, selectivity and excellent oral absorption in the rat.


L'unión médicale du Canada | 2001

Treatment of male sexual dysfunction

Alasdair Mark Naylor; Pieter Hadewijn Van Der Graaf; Christopher Peter Wayman


Journal of Medicinal Chemistry | 2006

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides

David C. Pryde; Graham Nigel Maw; Simon Paul Planken; Michelle Y. Platts; Vivienne Sanderson; Martin Corless; Alan Stobie; Christopher Gordon Barber; Rachel Jane Russell; Laura Foster; Laura Barker; Christopher Peter Wayman; Piet H. van der Graaf; Peter Stacey; Debbie Morren; Christopher Kohl; Kevin Beaumont; Sara Coggon; Michael S. Tute


Archive | 2004

Treatment of type 1 diabetes with pde5 inhibitors

Gillian Burgess; Earl Michael Gibbs; Christopher Peter Wayman


Archive | 2003

Treatment of female sexual dysfunction

Richard James Thurlow; Christopher Peter Wayman


Archive | 2000

Compounds for the treatment of female sexual dysfunction

Graham Nigel Maw; Christopher Peter Wayman

Researchain Logo
Decentralizing Knowledge